QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VII — Multiple Products, Substances and Marketing Authorisation Holders

Test your understanding of the concepts covered by GVP Module VII: Multiple Products, Substances and Marketing Authorisation Holders.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What should an MAH do if its regulatory database and safety product inventory show different products in scope?

Select whichever inventory is easier to use Finalize the PSUR and document the discrepancy afterward Reconcile the discrepancy against authoritative sources before finalising scope Exclude all products appearing only in one inventory

Question 2 of 10 During an inspection, an omitted product is identified. What would be the most defensible evidence of the MAH's scope decision?

The PSUR author's verbal explanation A documented scope inventory, authoritative source, inclusion or exclusion rationale, date, approval and impact assessment A statement that the product had low sales A copy of the product's promotional material

Question 3 of 10 Do different strengths automatically require separate PSURs?

Yes, because each strength is a separate safety universe Yes, unless the products share the same brand name No; the need for stratification depends on whether the strength or dose materially changes the safety evaluation No; strength can never be relevant to safety interpretation

Question 4 of 10 An MAH holds several authorisations for products containing the same active substance. What is generally the appropriate PSUR approach?

Prepare a separate PSUR for each product name in all circumstances Prepare one PSUR covering the relevant products, unless separate reports are otherwise specified or agreed Exclude products authorised through different regulatory procedures Combine only products with the same strength and indication

Question 5 of 10 Which evidence chain best demonstrates traceability of a material PSUR conclusion?

Draft conclusion, author memory and final approval Product name, sales forecast and submission date Regulatory scope, included products and authorisations, source systems, extraction, analysis and conclusion Partner contract, marketing plan and safety committee minutes

Question 6 of 10 Separate internal teams reach materially different conclusions about the same active substance. What should governance do first?

Select the conclusion from the team with the largest database Average the conclusions to create a neutral position Reconcile differences in cutoff, population, indication, formulation, exposure, methods and scientific interpretation Discard the conclusion that identifies the greater risk

Question 7 of 10 Which item is most important to include in a controlled PSUR scope inventory?

Only the commercial product names and annual sales targets Active substance, products, authorisations, indications, formulations, routes, MAHs and applicable reporting information Only products currently promoted in the EU Only products with newly identified safety signals

Question 8 of 10 What is the purpose of including a worldwide marketing authorisation perspective in the PSUR?

To replace the EU assessment with a global assessment To identify global authorisations, regulatory actions and safety information that may affect the overall and EU assessment To require identical product information in every jurisdiction To limit the report to centrally authorised products

Question 9 of 10 Which statement correctly distinguishes regulatory authorisation pathway from PSUR assessment scope?

Products authorised through different procedures must always have separate safety evaluations The authorisation pathway determines the product's pharmacological mechanism Separate regulatory procedures do not automatically require separate PSUR assessments when the applicable rules require a common active-substance scope PSUR scope is determined solely by whether an authorisation is centralised or national

Question 10 of 10 Why can excluding a relevant formulation from a PSUR affect the benefit-risk conclusion?

It changes the legal name of the active substance It may result in incomplete exposure, missed cases and inaccurate risk characterisation It automatically invalidates every product authorisation It prevents the MAH from using any international data

Knowledge Assessment: GVP Module VII — Multiple Products, Substances and Marketing Authorisation Holders

Cookie Settings